Auto-experimentation is a relatively unknown practice, albeit central to the history of medical discoveries. Outside of the context of research, auto-experimentation with psychotropic medications by psychiatrists currently persists in an informal manner. However, this contemporary practice has never been studied so far. This study was conducted by distributing an electronic questionnaire to French hospital-based psychiatrists and residents of psychiatry in the summer of 2016. Lifetime prevalence of taking psychotropic medications and the context of this ingestion were questioned: "therapeutic", "auto-therapeutic", "research protocol", "auto-experimentation/curiosity", "recreation" or "other". We only studied "auto-experimentation/curiosity" in this article. Participants were also asked their age and gender. Seven hundred and sixty-four participants were included. 15.1% of participants declared having already taken psychotropic medication at least once in the context of "auto-experimentation/curiosity". We found that those who reported taking medication for "auto-experimentation/curiosity" had a significant association with being male ( < .001) but no relationship to age. This practice highlights and questions psychiatry's relationship with formal and informal knowledge, the importance of the subjectivity of each professional in psychiatry and the epistemological foundations of our discipline. The strong ambivalence of the medical field toward this relatively taboo practice deserves further exploration.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/02791072.2019.1705445 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Psilocybin-assisted massed cognitive processing therapy for chronic posttraumatic stress disorder: Protocol for an open-label pilot feasibility trial.
PLoS One
January 2025
Interventional Psychiatry Program, St. Michael's Hospital, Toronto, Ontario, Canada.
Background: Posttraumatic stress disorder (PTSD) affects 3.9% of the general population. While massed cognitive processing therapy (CPT) has demonstrated efficacy in treating chronic PTSD, a substantial proportion of patients still continue to meet PTSD criteria after treatment, highlighting the need for novel therapeutic approaches.
View Article and Find Full Text PDFNeurodevelopmental and Mental Health Outcomes in a National Clinical Sample of Youth With Sex Chromosome Trisomies Compared With Matched Controls.
J Dev Behav Pediatr
January 2025
eXtraordinarY Kids Clinic and Research Program, Children's Hospital Colorado, Aurora, CO.
Objective: To compare the prevalence of neurodevelopmental and mental health diagnoses in a national sample of youth with sex chromosome trisomies (SCTs) with matched controls.
Methods: Patients in PEDSnet and a diagnosis code mapping to 47,XXY/Klinefelter syndrome (n = 1171), 47,XYY/Double Y syndrome (n = 243), or 47,XXX/Trisomy X syndrome (n = 262) were matched with controls using propensity scores. Generalized estimating equations computed odds ratios (OR) with 95% confidence intervals (CI) for the prevalence of diagnoses within the neurodevelopmental and mental health composites, psychotropic medication prescriptions, and encounters with behavioral health and therapy providers.
Prevalence of Popular Smoking Cessation Aids in England and Associations With Quit Success.
JAMA Netw Open
January 2025
Department of Behavioural Science and Health, University College London, London, United Kingdom.
Importance: A wide range of medications, noncombustible nicotine products, behavioral support, and alternative treatments are available in England to help people stop smoking. Understanding their effectiveness outside of clinical trial settings can support informed decision-making.
Objectives: To provide up-to-date estimates of the prevalence of different smoking cessation aids and associations with quit success and to explore moderation by socioeconomic position.
Exploring the Potential of Psychedelics in the Treatment of Headache Disorders: Clinical Considerations and Exploratory Insights.
Curr Pain Headache Rep
January 2025
Northwell Health Department of Neurology, New York, NY, USA.
Purpose Of Review: Exploration of the potential of serotonergic psychedelic drugs, such as psilocybin and LSD, as potential treatments for headache disorders. This review addresses the need for well-informed physician guidelines and discusses mechanisms, safety, and efficacy of these treatments. Further research, including the consideration of combination with psychotherapy, is needed.
View Article and Find Full Text PDFImpact of Anticholinergic Burden on Cognitive Functions in Individuals with Bipolar Disorder, Schizoaffective Disorder, and Schizophrenia.
Clin Psychopharmacol Neurosci
February 2025
Department of Psychiatry, Pamukkale University, Denizli, Türkiye.
Objective: Bipolar disorder (BD), schizoaffective disorder (SAD), and schizophrenia (SCH) are psychiatric disorders characterized by persistent cognitive impairments, even during periods of remission. Psychotropic medications commonly used to manage these conditions have anticholinergic properties, which may contribute to cognitive impairment.
Methods: This study examined the relationship between anticholinergic medication burden and cognitive function in individuals diagnosed with BD, SAD, and SCH.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!